Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului
Yüklə 4,39 Mb.
|
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului. ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac L04AA05 TACROLIMUSUM CAPS. 1 mg PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD. Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. 5 mg PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac ________________________________________________________________________________ ______________________________________________________________________________ | 936 |L04AA06| MYCOPHENOLATUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD. Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac. L04AA06 MYCOPHENOLATUM CAPS. 250 mg CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD. MYFENAX 250 mg 250 mg TEVA PHARMA BV
MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH L04AA06 MYCOPHENOLATUM CAPS. 500 mg MYFENAX 500 mg 500 mg TEVA PHARMA BV L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD. Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac. L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg SOL. PERF. CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.
| 937 |A05AA02| ACIDUM URSODEOXYCHOLICUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A05AA02 ACIDUM CAPS. 250 mg URSODEOXYCHOLICUM URSOFALK(R) 250 mg DR. FALK PHARMA GMBH URSOSAN 250 mg PRO. MED. CS PRAHA AS ________________________________________________________________________________ ______________________________________________________________________________ | 938 |B01AB05| ENOXAPARINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS anti-Xa/0.4 ml
anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui anti-Xa/0.8 ml CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS anti-Xa/0.8 ml B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS anti-Xa/0.4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml ________________________________________________________________________________
| 939 |B01AB08| REVIPARINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG ________________________________________________________________________________
| 940 |B01AC11| ILOPROSTUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AC11 ILOPROSTUM CONC. PT. SOL. PERF. 20 µg/ml ILOMEDIN(R) 20 20 µg/ml SCHERING AG ________________________________________________________________________________ ______________________________________________________________________________ | 941 |B01AD02| ALTEPLASUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AD02 ALTEPLASUM LIOF. + SOLV. PT. SOL. 50 mg INJ. ACTILYSE 50 mg BOEHRINGER INGELHEIM INT. GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 944 |C03EB01| COMBINAŢII (SPIRONOLACTONUM + FUROSEMIDUM) | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ C03EB01 COMBINAŢII CAPS. (SPIRONOLACTONUM + FUROSEMIDUM) DIUREX 50 TERAPIA SA ________________________________________________________________________________ ______________________________________________________________________________ | 945 |H01BA02| DESMOPRESSINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01BA02 DESMOPRESSINUM MINIRIN 0,2 mg 0.2 mg FERRING AB
MINIRIN 0,2 mg 0.2 mg FERRING AB ________________________________________________________________________________
| 946 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ. TAZOBACTAMUM TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 947 |J01XX08| LINEZOLIDUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG ________________________________________________________________________________
| 948 |J02AC03| VORICONAZOLUM** | Protocol: J012B | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AC03 VORICONAZOLUM COMPR. FILM. 200 mg VFEND 200 mg 200 mg PFIZER LTD.
VFEND 200 mg 200 mg PFIZER LTD. J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA 40 mg/ml VFEND 40 mg/ml 40 mg/ml PFIZER LTD. J02AC03 VORICONAZOLUM COMPR. FILM. 50 mg VFEND 50 mg 50 mg PFIZER LTD. ________________________________________________________________________________
| 949 |J02AX04| CASPOFUNGINUM** | Protocol: J010D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 50 mg SOL. PERF. CANCIDAS 50 mg 50 mg MERCK SHARP & DOHME LTD J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 70 mg SOL. PERF. CANCIDAS 70 mg 70 mg MERCK SHARP & DOHME LTD ________________________________________________________________________________ ______________________________________________________________________________ | 951 |J05AB14| VALGANCICLOVIRUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL ________________________________________________________________________________ ______________________________________________________________________________ | 953 |L03AA02| FILGRASTIMUM (G-CSF) | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V. ________________________________________________________________________________
| 954 |L04AA01| CICLOSPORINUM | | |_______|_______|____________________________________________|_________________|
Monitorizarea atentă a pacienţilor este obligatorie. Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului. ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA01 CICLOSPORINUM CAPS. MOI 100 mg EQUORAL(R) 100 mg 100 mg IVAX - PHARMACEUTICALS S.R.O.
EQUORAL(R) 100 mg/ml IVAX - PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 100 mg/ml NOVARTIS PHARMA GMBH L04AA01 CICLOSPORINUM CAPS. MOI 25 mg CICLORAL(R) HEXAL(R) 25 mg 25 mg HEXAL AG EQUORAL(R) 25 mg 25 mg IVAX - PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 25 mg NOVARTIS PHARMA GMBH L04AA01 CICLOSPORINUM CAPS. MOI 50 mg CICLORAL(R) HEXAL 50 mg 50 mg HEXAL AG EQUORAL(R) 50 mg 50 mg IVAX - PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 50 mg NOVARTIS PHARMA GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 955 |L04AA05| TACROLIMUSUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. 1 mg PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD. L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. 5 mg PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH ________________________________________________________________________________
| 956 |L04AA06| MYCOPHENOLATUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD. Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic L04AA06 MYCOPHENOLATUM CAPS. 250 mg CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD. MYFENAX 250 mg 250 mg TEVA PHARMA BV
MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH L04AA06 MYCOPHENOLATUM CAPS. 500 mg MYFENAX 500 mg 500 mg TEVA PHARMA BV Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD. L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg SOL. PERF. CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 957 |L04AA10| SIROLIMUS** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA10 SIROLIMUS COMPR. FILM. 1 mg RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
| 958 |A05AA02| ACIDUM URSODEOXYCHOLICUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A05AA02 ACIDUM CAPS. 250 mg URSODEOXYCHOLICUM URSOFALK(R) 250 mg DR. FALK PHARMA GMBH URSOSAN 250 mg PRO. MED. CS PRAHA AS ________________________________________________________________________________ ______________________________________________________________________________ | 959 |A11CC03| ALFACALCIDOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS SRL ________________________________________________________________________________
| 960 |B01AB05| ENOXAPARINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml
anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS anti-Xa/0.4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui anti-Xa/0.8 ml CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS anti-Xa/0.8 ml B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS anti-Xa/0.4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml ________________________________________________________________________________
| 961 |B01AB04| DALTEPARINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB04 DALTEPARINUM SOL. INJ. 10000 ui/ml FRAGMIN 10000 UI/ml 10000 ui/ml PFIZER EUROPE MA EEIG
FRAGMIN 15000 UI/0,6 ml 15000 ui/0.6 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 2500 ui/0.2 ml FRAGMIN 2500 UI/0,2 ml 2500 ui/0.2 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 5000 ui/0.2 ml FRAGMIN 5000 UI/0,2 ml 5000 ui/0.2 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 7500 ui/0.3 ml FRAGMIN 7500 UI/0,3 ml 7500 ui/0.3 ml PFIZER EUROPE MA EEIG ________________________________________________________________________________
| 962 |B01AB08| REVIPARINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml CLIVARIN(R) 1432 UI/0,25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG ________________________________________________________________________________
______________________________________________________________________________ | 965 |B05AA06| POLYGELINUM | | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B05AA06 POLYGELINUM SOL. PERF. 3.5% HAEMACCEL 3.5% THERASELECT GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 966 |H01CB02| OCTREOTIDUM** | Protocol: H010C | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H01CB02 OCTREOTIDUM SOL. INJ. 0.1 mg/ml SANDOSTATIN(R) 0.1 mg/ml NOVARTIS PHARMA GMBH
INJ. (I.M.) CU ELIB. PRELUNG. SANDOSTATIN LAR 10 mg 10 mg NOVARTIS PHARMA GMBH H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 20 mg INJ. (I.M.) CU ELIB. PRELUNG. SANDOSTATIN LAR 20 mg 20 mg NOVARTIS PHARMA GMBH H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 30 mg INJ. (I.M.) CU ELIB. PRELUNG. SANDOSTATIN LAR 30 mg 30 mg NOVARTIS PHARMA GMBH ________________________________________________________________________________
| 967 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ. TAZOBACTAMUM TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 968 |J01XA02| TEICOPLANINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01XA02 TEICOPLANINUM LIOF. + SOLV. PT. SOL. 400 mg INJ. TARGOCID(R) 400 mg 400 mg AVENTIS PHARMA LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 969 |J01XX08| LINEZOLIDUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG ________________________________________________________________________________
| 970 |J02AB02| KETOCONAZOLUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|